MX2020002883A - Método y composiciones para tratar la infección viral. - Google Patents
Método y composiciones para tratar la infección viral.Info
- Publication number
- MX2020002883A MX2020002883A MX2020002883A MX2020002883A MX2020002883A MX 2020002883 A MX2020002883 A MX 2020002883A MX 2020002883 A MX2020002883 A MX 2020002883A MX 2020002883 A MX2020002883 A MX 2020002883A MX 2020002883 A MX2020002883 A MX 2020002883A
- Authority
- MX
- Mexico
- Prior art keywords
- viral infection
- composition
- treating viral
- treating
- togaviriade
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title abstract 4
- 230000009385 viral infection Effects 0.000 title abstract 4
- 241000711950 Filoviridae Species 0.000 abstract 1
- 241000710781 Flaviviridae Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 229940097217 cardiac glycoside Drugs 0.000 abstract 1
- 239000002368 cardiac glycoside Substances 0.000 abstract 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 abstract 1
- 229930002534 steroid glycoside Natural products 0.000 abstract 1
- 150000003648 triterpenes Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2017/051553 WO2018053123A1 (fr) | 2016-09-14 | 2017-09-14 | Méthodes et compositions de traitement d'infections virales |
| US201862698365P | 2018-07-16 | 2018-07-16 | |
| PCT/US2018/042226 WO2019055119A1 (fr) | 2017-09-14 | 2018-07-16 | Méthode et composition pour le traitement d'une infection virale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002883A true MX2020002883A (es) | 2020-10-05 |
Family
ID=65723839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002883A MX2020002883A (es) | 2017-09-14 | 2018-07-16 | Método y composiciones para tratar la infección viral. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3681508A4 (fr) |
| JP (3) | JP6820450B2 (fr) |
| KR (2) | KR102295179B1 (fr) |
| AU (2) | AU2018334386B2 (fr) |
| CA (1) | CA3075729A1 (fr) |
| IL (2) | IL285232B (fr) |
| MX (1) | MX2020002883A (fr) |
| RU (1) | RU2020113341A (fr) |
| WO (1) | WO2019055119A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220151038A (ko) | 2020-03-31 | 2022-11-11 | 피닉스 바이오테크놀러지 인코포레이티드. | 코로나바이러스 감염 예방를 위한 조성물 |
| ES2965161T3 (es) * | 2020-03-31 | 2024-04-11 | Phoenix Biotechnology Inc | Método y composiciones para el tratamiento de infección por coronavirus |
| EP4295854A3 (fr) | 2020-03-31 | 2024-04-03 | Phoenix Biotechnology, Inc. | Méthode et compositions pour le traitement d'une infection à coronavirus |
| US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
| FR3109297A1 (fr) * | 2020-04-19 | 2021-10-22 | Ephyla | « Nouvel inhibiteur non protéique de furine » |
| WO2022094816A1 (fr) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Formulation solide |
| US12465645B2 (en) * | 2022-04-01 | 2025-11-11 | Alexia Reif | Anti-viral composition and method for preparing the same |
| KR102704483B1 (ko) * | 2023-02-28 | 2024-09-10 | 대한민국(질병관리청 국립보건연구원장) | 스테로이드 유도체 계열 화합물 및 이를 유효성분으로 함유하는 항바이러스제 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK239687A (da) | 1986-05-13 | 1987-11-14 | Huseyin Ziya Ozel | Planteekstrakter |
| US5236132A (en) | 1992-01-03 | 1993-08-17 | Vortec, Inc. | Gradient-force comminuter/dehydrator apparatus and method |
| US5598979A (en) | 1995-04-20 | 1997-02-04 | Vortec, Inc. | Closed loop gradient force comminuting and dehydrating system |
| CA2191923C (fr) | 1996-12-03 | 2000-10-24 | Ji-Won Yoon | Portulaca oleracea et croissance des cellules tumorales |
| CA2330916C (fr) | 1998-05-19 | 2011-04-05 | Research Development Foundation | Compositions de triterpene et leurs champ d'application |
| US6565897B2 (en) | 1998-09-24 | 2003-05-20 | Ozelle Pharmaceuticals, Inc. | Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof |
| US6517015B2 (en) | 2000-03-21 | 2003-02-11 | Frank F. Rowley, Jr. | Two-stage comminuting and dehydrating system and method |
| AU8494601A (en) | 2000-08-18 | 2002-03-04 | Univ Illinois | Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV |
| US9931316B2 (en) * | 2004-01-06 | 2018-04-03 | Paul Edward Stamets | Antiviral activity from medicinal mushrooms and their active constituents |
| US6715705B2 (en) | 2001-03-16 | 2004-04-06 | Frank F. Rowley, Jr. | Two-stage comminuting and dehydrating system and method |
| DE60204078T2 (de) | 2001-04-09 | 2006-01-26 | Loders Croklaan B.V. | Konzentrat von Triterpenen |
| EP2567625A1 (fr) | 2001-05-11 | 2013-03-13 | University Of Ottawa | Préparation à base d'acide bétulinique obtenue à partir d'une plante de la famille des Marcgraviaceae |
| US20040082521A1 (en) | 2002-03-29 | 2004-04-29 | Azaya Therapeutics Inc. | Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| WO2003099011A1 (fr) * | 2002-05-28 | 2003-12-04 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Utilisation de glucosides cardiotoniques pour le traitement de la mucovicidose et autres troubles dependant de il-8 |
| EP1585504A4 (fr) | 2002-11-06 | 2009-07-15 | Azaya Therapeutics Inc | Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines |
| WO2004087121A2 (fr) | 2003-03-28 | 2004-10-14 | Azaya Therapeutics, Inc. | Formulations hydrosolubles de glycoside digitaux en vue du traitement de la proliferation cellulaire et d'autres maladies |
| BRPI0508854A (pt) | 2004-03-17 | 2007-08-28 | Panacos Pharmaceuticals Inc | sais farmacêuticos de ácido-3-o-(3',3'-dimetilsuccinil) betulìnico |
| US7118508B2 (en) | 2004-07-28 | 2006-10-10 | General Motors Corporation | Planetary transmissions having three interconnected gear members and clutched input members |
| WO2006085334A2 (fr) | 2005-02-09 | 2006-08-17 | Dabur Pharma Limited | Nouveaux derives d'acide betulinique |
| AU2006230429A1 (en) | 2005-03-29 | 2006-10-05 | Regents Of The University Of Minnesota | Selective oxidation of triterpenes employing TEMPO |
| US20060252733A1 (en) | 2005-04-07 | 2006-11-09 | Novelix Pharmaceuticals, Inc. | Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism |
| US20090131714A1 (en) | 2005-06-08 | 2009-05-21 | Krasutsky Pavel A | Synthesis of betulonic and betulinic aldehydes |
| JP5080249B2 (ja) | 2005-06-10 | 2012-11-21 | ポーラ化成工業株式会社 | 新規トリテルペン酸誘導体及びそれを含有してなる皮膚外用剤 |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| CN101374527A (zh) | 2005-12-16 | 2009-02-25 | 帕纳克斯医药公司 | 3-o-(3’,3’-二甲基琥珀酰基)桦木酸的药物盐的制备方法 |
| EP1803461A1 (fr) * | 2005-12-27 | 2007-07-04 | Heinz-Herbert Fiebig | Utilisation therapeutique d'un extrait de feuilles de Nerium oleander |
| GB0604535D0 (en) | 2006-03-07 | 2006-04-12 | Sndv Sprl | Betulonic acid derivatives |
| WO2008063318A2 (fr) | 2006-10-12 | 2008-05-29 | The Texas A & M University System And Safe Et Al | Acide bétulinique, dérivés et analogues de celui-ci, et leurs utilisations |
| CA2668452A1 (fr) | 2006-11-03 | 2008-05-15 | Panacos Pharmaceuticals, Inc. | Derives de triterpene etendus |
| WO2008091532A1 (fr) | 2007-01-19 | 2008-07-31 | Panacos Pharmaceuticals, Inc. | Sels de l'acide 3-o-(3',3'-diméthylsuccinyl)bétulinique et leurs formes à l'état solide |
| US8987212B2 (en) | 2007-08-07 | 2015-03-24 | Muhammed Majeed | Oleanoyl peptide composition and method of treating skin aging |
| CA2705272C (fr) | 2007-11-13 | 2020-05-12 | Phoenix Biotechnology Inc. | Procede de determination de la probabilite d'une reponse therapeutique dans la chimiotherapie anticancereuse avec un glycoside cardiaque |
| US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| KR101713140B1 (ko) | 2008-04-18 | 2017-03-08 | 리타 파마슈티컬스 잉크. | Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체 |
| MX2010011439A (es) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17. |
| JP5529851B2 (ja) | 2008-04-18 | 2014-06-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体 |
| US20110224159A1 (en) | 2008-09-10 | 2011-09-15 | Universite du Quebec a Chicoutime | Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents |
| WO2010053817A1 (fr) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Dérivés de l’acide bétulinique et leurs méthodes d’utilisation |
| US8802727B2 (en) | 2009-07-14 | 2014-08-12 | Hetero Research Foundation, Hetero Drugs Limited | Pharmaceutically acceptable salts of betulinic acid derivatives |
| CN101704872B (zh) | 2009-11-23 | 2012-06-27 | 张南 | 23-羟基白桦酸衍生物、其制备方法及应用 |
| US8685469B2 (en) | 2009-11-30 | 2014-04-01 | University Of Kwazulu-Natal | In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives |
| US9011937B2 (en) | 2010-11-22 | 2015-04-21 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
| KR101811462B1 (ko) | 2010-01-11 | 2018-01-25 | 피닉스 바이오테크놀러지 인코포레이티드. | 협죽도 추출물을 포함하는 신경질환 치료용 조성물 |
| TWI386415B (zh) | 2010-02-02 | 2013-02-21 | Univ Kaohsiung Medical | 熊果酸衍生物及其醫藥組合物 |
| TWI410431B (zh) | 2010-12-22 | 2013-10-01 | Ind Tech Res Inst | 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途 |
| US20140221328A1 (en) | 2011-01-10 | 2014-08-07 | Bandi Parthasaradhi Reddy | Pharmaceutically acceptable salts of novel betulinic acid derivatives |
| HUE026371T2 (en) | 2011-01-31 | 2016-05-30 | Bristol Myers Squibb Co | C-28 amines from modified C-3 betulinic acid derivatives as anti-HIV matrices |
| CN102558280B (zh) | 2011-11-18 | 2014-09-17 | 温州大学 | 一种30-卤代桦木酸的生产方法 |
| JP6211527B2 (ja) | 2011-12-01 | 2017-10-11 | ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | ２−置換オレアノール酸誘導体、その調製方法及びその用途 |
| CN103946231B (zh) | 2011-12-01 | 2016-10-26 | 杭州本生药业有限公司 | 齐墩果酸酰胺化衍生物、及其制备方法和应用 |
| WO2013160810A2 (fr) | 2012-04-24 | 2013-10-31 | Hetero Research Foundation | Nouveaux dérivés d'acide bétulinique à titre d'inhibiteurs du vih |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| WO2014027777A2 (fr) | 2012-08-14 | 2014-02-20 | 한국콜마 주식회사 | Nouveau dérivé d'acide ursolique et son procédé de préparation |
| JP6243428B2 (ja) | 2012-09-10 | 2017-12-06 | リアタ ファーマシューティカルズ インコーポレイテッド | オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法 |
| SMT201700501T1 (it) | 2012-09-10 | 2017-11-15 | Reata Pharmaceuticals Inc | Derivati c17-eteroarilici dell'acido oleanolico e metodi d'uso degli stessi |
| WO2014040073A1 (fr) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | Dérivés c13-hydroxy de l'acide oléanolique et leurs procédés d'utilisation |
| US9637516B2 (en) | 2012-12-31 | 2017-05-02 | Hetero Research Foundation | Betulinic acid proline derivatives as HIV inhibitors |
| KR20150121712A (ko) | 2013-02-25 | 2015-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체 |
| EP3105241A1 (fr) * | 2014-02-12 | 2016-12-21 | Organo Balance GmbH | Souche de levure et procédé microbien de production de triterpènes et/ou triterpénoïdes pentacycliques |
| WO2015195776A1 (fr) | 2014-06-19 | 2015-12-23 | Bristol-Myers Squibb Company | Dérivés d'acide bétulinique présentant une activité inhibitrice de maturation du vih |
| US9492438B2 (en) * | 2014-07-25 | 2016-11-15 | Bette Pollard | Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system |
| WO2016200672A1 (fr) * | 2015-06-08 | 2016-12-15 | Cutanea Life Sciences, Inc. | Composition thérapeutique |
-
2018
- 2018-07-16 CA CA3075729A patent/CA3075729A1/fr active Pending
- 2018-07-16 WO PCT/US2018/042226 patent/WO2019055119A1/fr not_active Ceased
- 2018-07-16 RU RU2020113341A patent/RU2020113341A/ru unknown
- 2018-07-16 KR KR1020207007406A patent/KR102295179B1/ko not_active Expired - Fee Related
- 2018-07-16 AU AU2018334386A patent/AU2018334386B2/en not_active Ceased
- 2018-07-16 KR KR1020217026676A patent/KR20210107904A/ko not_active Abandoned
- 2018-07-16 MX MX2020002883A patent/MX2020002883A/es unknown
- 2018-07-16 EP EP18857189.7A patent/EP3681508A4/fr not_active Withdrawn
- 2018-07-16 JP JP2020515911A patent/JP6820450B2/ja not_active Expired - Fee Related
- 2018-07-16 IL IL285232A patent/IL285232B/en unknown
-
2020
- 2020-03-09 IL IL273162A patent/IL273162B/en unknown
- 2020-06-25 AU AU2020204236A patent/AU2020204236B2/en not_active Ceased
-
2021
- 2021-01-04 JP JP2021000190A patent/JP7037673B2/ja not_active Expired - Fee Related
-
2022
- 2022-03-04 JP JP2022033642A patent/JP2022075755A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021063105A (ja) | 2021-04-22 |
| KR102295179B1 (ko) | 2021-08-30 |
| IL285232A (en) | 2021-09-30 |
| RU2020113341A3 (fr) | 2021-10-15 |
| AU2018334386B2 (en) | 2021-11-04 |
| IL285232B (en) | 2022-07-01 |
| EP3681508A4 (fr) | 2021-05-19 |
| CA3075729A1 (fr) | 2019-03-21 |
| JP7037673B2 (ja) | 2022-03-16 |
| WO2019055119A1 (fr) | 2019-03-21 |
| JP6820450B2 (ja) | 2021-01-27 |
| AU2020204236B2 (en) | 2020-12-10 |
| IL273162B (en) | 2021-08-31 |
| JP2020534293A (ja) | 2020-11-26 |
| IL273162A (en) | 2020-04-30 |
| EP3681508A1 (fr) | 2020-07-22 |
| KR20200081356A (ko) | 2020-07-07 |
| JP2022075755A (ja) | 2022-05-18 |
| RU2020113341A (ru) | 2021-10-15 |
| AU2018334386A1 (en) | 2020-04-02 |
| KR20210107904A (ko) | 2021-09-01 |
| AU2020204236A1 (en) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002883A (es) | Método y composiciones para tratar la infección viral. | |
| PH12020550114A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| PH12016502564A1 (en) | Substituted nucleosides, nucleosides and analogs thereof | |
| PH12020550531A1 (en) | Novel, highly active pyrazolo-piperidine substituted indole2-carboxamides active against the hepatitis b virus (hbv) | |
| PH12022550033A1 (en) | Compounds useful to treat influenza virus infections | |
| NZ745328A (en) | Methods for treating filoviridae virus infections | |
| EA030115B9 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| PH12016502563A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| JOP20180098A1 (ar) | : مركبات علاجية مفيدة للوقاية من أو علاج الإصابة بفيروس نقص المناعة البشرية | |
| MX2023004969A (es) | Metodos para tratar y prevenir infeccion por c. difficile. | |
| WO2019086141A8 (fr) | Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb) | |
| PH12018502058A1 (en) | Thiazolide compounds for treating viral infections | |
| MX2019002978A (es) | Composiciones que comprenden una bacteria no patogena y metodos para proteger plantas y animales anfitriones contra enfermedades micoticas, bacterianas y virales. | |
| PH12015502230A1 (en) | Novel viral replication inhibitors | |
| MX2018002707A (es) | Derivados de tetrahidrofurano antivirales. | |
| MX2017005350A (es) | Terapia para la inhibicion de la replicacion del virus de arn monocatenario. | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| PH12016500465A1 (en) | Deoxynojirimycin derivatives and methods of their using | |
| PH12016502001A1 (en) | Novel bacteriophage and composition comprising same | |
| GB2544439A (en) | Antiviral composition | |
| MX2018009543A (es) | Metodo para tratar la infección por el virus del zika con composiciones que contienen quercetina. | |
| JOP20190214A1 (ar) | ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها | |
| PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
| PH12017500817A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
| PH12016502000A1 (en) | Novel bacteriophage and composition comprising same |